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Abstract 
Purpose: To investigate the neuroprotective potential of apocynin nitrone (AN-1), a nitrone analogue of 
apocynin, in rat brain tissue as a novel candidate for ischemic stroke treatment. 
Methods: In vitro neuroprotection of AN-1 was studied in SH-SY5Y cells treated with oxygen glucose 
deprivation (OGD). Cell viability was measured using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) assay, and intracellular reactive oxygen species (ROS) level was 
investigated using flow cytometry. The protection of AN-1 in cerebral ischemia-reperfusion (I/R) rats was 
evaluated by cerebral infarct area and neurological deficit score. Oxidative stress of the ischemic 
hemisphere was assessed by malondialdehyde (MDA), glutathione (GSH) and superoxide dismutase 
(SOD) levels. 
Results: In OGD-treated SH-SY5Y cells, AN-1 reduced cell death and ROS level. In I/R rats, AN-1 
exerted potential protection against neurological deficit by reducing infarction area, decreasing 
neurological deficit score and relieving oxidative stress. AN-1 exhibited stronger action than its parent 
compound apocynin in vitro, but the two had similar effects in vivo. In addition, AN-1 demonstrated 
efficacy close to or higher than the positive reference Edaravone® both in vitro and in vivo. 
Furthermore, AN-1 showed lower toxicity than apocynin in vitro. 
Conclusion: The results suggest that AN-1 may be a potential neuroprotective agent for the treatment 
of ischemic stroke in human. 
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Ischemic stroke is a disturbance caused by 
occlusion of the cerebral vasculature, which lead 
to decreased delivery of glucose and oxygen to 
the brain, disruption of the ionic equilibrium and 
calcium homeostasis, excitotoxicity and eventual 
cell death [1,2]. It is one of the leading causes of 
death and disability worldwide. However, few 
therapeutic methods or drugs have adequate 
effects in the clinical treatment of ischemic stroke 
[2,3]. Timely recanalization of cerebral artery 
vessels and reintroduction of blood flow allow 
ischemic stroke-induced impairments to be 
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arrested and reversed, thus, it is considered as 
an efficient therapy [3]. In ischemic cerebral 
injury, besides the ischemic infarction, the 
reperfusion after ischemia brings oxidative injury 
induced by reactive oxygen species (ROS) as 
well, which might cause delayed neuronal death 
[3]. To prevent irreversible ischemic injury, 
neuroprotection is essential [2-4]. In ischemia-
reperfusion (I/R), superoxide anion is one of the 
most important ROS, as it contributes to 
oxidative injury in the progress of ischemic stroke 
[5]. NADPH oxidase (NOX) can effectively 
generate superoxide anion, which further 
interacts with nitric oxide to form peroxynitrite, 
another key reactive species accounting for 
neuronal death [6]. NOX is a major mediator 
involved in I/R-induced neuronal death. Thus, 
NOX inhibitors or genetic deletion of NOX have 




none), a natural compound in the root of 
Picrorhiza kurroa Royle, is able to specifically 
block the activity of NOX by preventing the 
transfer of its cytosolic subunit to membrane [7]. 
In previous researches, Apo was reported to 
improve ischemic infarction and show 
neuroprotection against middle cerebral artery 
occlusion (MCAO)-induced impairments in wild-
type rodent models but not in NOX2-deficient 
mice [7,8]. However, Tang et al reported that the 
therapeutic dose range of Apo was quite narrow 
in experimental stroke [9]. Hence, new apocynin 
analogues were designed and synthesized in our 
lab to explore promising candidates in treating 
ischemic stroke [10]. 
 
Nitrones were originally developed as free radical 
trapping agents in free radical chemistry [11]. 
Recently, it was discovered that nitrones 
protected biological systems against oxidative 
stress induced impairments [11-14]. Nitrones 
have been tested as therapeutic agents for 
various diseases, including stroke [11,12]. In light 
of the neuroprotective activity of both apocynin 
and nitrones, we synthesized apocynin nitrone 
(AN-1) by conjugating apocynin with a nitrone 
moiety at the ortho position of its phenolic 
hydroxyl group [10]. 
 
In previous studies, AN-1 showed relatively good 
NADPH oxidase inhibition and activity against 
oxidative injury both in vitro and in vivo, 
compared with its parent apocynin [15,16]. In this 
work, AN-1 was further studied for its efficacy on 
ischemic stroke through neuroprotective 
investigation. To evaluate the efficacy of AN-1, 
human neuroblastoma cell line (SH-SY5Y) 
treated by oxygen glucose deprivation (OGD) 
followed by reoxygenation was used for test in 
vitro, and rats with cerebral I/R caused by middle 
cerebral artery occlusion (MCAO) were studied in 
vivo. For comparison, Edaravone® (Eda), a 
powerful free-radical scavenger often used in 
cerebral I/R injury studies [17,18], was used as a 
positive reference, and the parent Apo was 




Chemicals and reagents 
 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), dimethyl 
sulfoxide (DMSO), triphenyltetrazolium chloride 
(TTC) and 2',7'-dichlorofluorescein diacetate 
(DCFH-DA) were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). Dulbecco's Modified Eagle 
Medium (DMEM), fetal blood serum (FBS) and 
penicillin-streptomycin solution (100×) were 
supplied by Gibco (Shanghai, China). Assay kits 
for glutathione (GSH), malondialdehyde (MDA) 
and superoxide dismutase (SOD) were provided 
by Nanjing Jiancheng Bioengineering Institute 
(Nanjing, China). All other reagents were 
purchased from Sigma-Aldrich unless stated 
otherwise. 
 
Cell culture under normal and OGD condition 
 
Under normal condition, the human 
neuroblastoma cell line SH-SY5Y (purchased 
from ATCC) was maintained in DMEM containing 
10 % FBS and supplemented with 100 U/mL 
penicillin and 100 g/mL streptomycin in a 
humidified atmosphere containing 5 % CO2 at 37 
ºC. Under OGD condition, the cells were 
incubated in glucose-free DMEM at 37 ºC in a tri-
gas incubator with 95 % N2 and 5 % CO2. 
 
Cell protection effect by MTT assay 
 
The cell protection effect of the tested agents 
was measured by MTT assy. All compounds 
including AN-1 were dissolved in DMSO and 
freshly prepared before use (final culture 
concentration of DMSO < 0.1 %). SH-SY5Y cells 
were dispensed in 96-well plate at a density of 1 
× 105 cells per well. After 24 h incubation under 
normal condition (5 % CO2 at 37 ºC), cells were 
treated with the tested agents for 8 h under OGD 
condition, and the cells were continuously 
cultured for an additional 12 h under normal 
condition. A 10 µl aliquot of 0.5 % MTT solution 
was added to each well followed by 4 h of 
incubation. Then, the medium was discarded and 
100 μl of DMSO was added to each well to 
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dissolve the formazan. The optical density of 
each well was measured at 570 nm using a 
microplate reader (Spectra MAX 340, Molecular 
Devices Co, CA, USA). Cell viability was 
expressed as a percentage of the value of 
control cells. 
 
Intracellular ROS assay 
 
SH-SY5Y cells were seeded on 6-well plates at a 
density of 5 × 105 cells/well, and OGD insult was 
generated as described above. After 1 h of OGD 
insult, cells were washed with phosphate-
buffered saline (PBS) and incubated with 10 μM 
DCFH-DA for 20 min. The cells were collected by 
D-hanks buffer at a density of 1 × 105 - 1 × 106 
cells/mL. The intracellular ROS concentration 
was measured using DCFH-DA fluorescent 
probe and a flow cytometer (Becton, Dickinson 
and Company, NJ, USA). 
 
Animals and grouping 
 
Male Sprague-Dawley (SD) rats (250 ± 10 g) 
were obtained from Medical Experimental Animal 
Center of Guangdong Province. The animals 
were housed at a constant temperature (24 ± 1 
°C) in a humidity-controlled (60 ± 10 %) 
environment under a 12 h light/dark cycle, and 
given standard laboratory food and water ad 
libitum. All animals were kept 7 days for 
acclimation before the experiments. All animal 
studies were approved and conducted in 
accordance with the Guidelines of Laboratory 
Animal Ethics Committee of Jinan University 
(approval ref no. 20140408110751). All animal 
procedures used in this study were also 
conducted with reference to the Guide for the 
Care and Use of Laboratory Animals (8th edition) 
of the National Research Council (US) [19]. The 
rats were divided randomly into seven groups, as 
follows: control, I/R alone, I/R with apocynin (2 
mg/kg), I/R with Eda (6 mg/kg), I/R with a low 
dose of AN-1 (1.5 mg/kg), I/R with a medium 
dose of AN-1 (3 mg/kg), and I/R with a high dose 
of AN-1 (6 mg/kg). 
 
Animal surgical procedures 
 
Rats were anesthetized with chloral hydrate (10 
%), which provided a stable plane of anesthesia 
for the full duration of the experiment. The right 
common carotid artery was exposed, the external 
carotid artery (ECA) and internal carotid artery 
(ICA) were isolated. The ECA was dissected 
distally, a coated suture (4.0 monofilament nylon 
suture, Beijing Sunbio Biotech Co. Ltd, Beijing, 
China) was introduced into the ECA lumen, and 
then gently advanced into the ICA lumen to block 
middle cerebral artery (MCA) blood flow. 
Following this, the incision was closed and 
penicillin was given intraperitoneally to prevent 
inflammation. Two hours after occlusion, Apo, 
Eda and AN-1 were administered via the tail 
vein. Five minutes later, the suture was removed 
to restore blood flow. Sham-operated rats were 
manipulated similarly, except MCA was not 
occluded. Regional cerebral blood flow (rCBF) 
was monitored by laser-Doppler flowmeter 
(Periflux System 5000, Perimed Inc.) with a 
flexible probe over the skull. rCBF was measured 
before ischemia, during MCAO and after 
reperfusion. Animals that did not show rCBF 
reduction of at least 70 % and animals that died 
after ischemia induction were excluded. A 
successful animal model showed a significant 
rCBF reduction after MCAO and obvious rCBF 
restoration after removing the suture. Core body 
temperature was monitored with a rectal probe 
and maintained at 37 °C throughout the 
procedure. All surgical procedures were 
performed under an operating stereomicroscope. 
 
Measurement of neurological deficit 
 
Neurological deficit of all the rats was measured 
using the Longa method at 24 h after reperfusion 
[20]. A 5-point scoring system was used, as 
follows: 0, no detectable deficit; 1, inability to 
extend the contralateral forelimb; 2, mild circling 
to the contralateral side; 3, falling to the 
contralateral side; and 4, no spontaneous motor 
activity. Neurological assessment was performed 
by an investigator blinded to the experimental 
treatment. After neurological behavior testing, the 
animals were euthanized, and the brains were 
collected for measurement of the cerebral infarct 
area and anti-oxidative activity. 
 
Measurement of the cerebral infarct area 
 
The brain of each rat was quickly removed, 
chilled at -20 °C for 20 min, and then sliced into 2 
mm coronal sections using a rat brain matrix 
(Harvard Apparatus, Holliston, MA, USA). 
Sections were incubated in a 1 % TTC solution at 
37 °C for 30 min and fixed with 4 % formalin 
solution. The images of the sections were 
captured using a digital camera on a solid-
colored background plate that was neither red 
nor white. The infarct area was measured using 
Image J software and calculated as follows in Eq. 
1. 
 
Infarct area (%) = {I-(R-L)}/L × 100…………. (1) 
 
where I is the area of ischemic region, R the area 
of ischemic right hemisphere, and L the area of 
normal left hemisphere. 
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Evaluation of anti-oxidative activity 
 
For each rat, the ischemic hemisphere was 
dissected out and homogenized in PBS buffer. 
The samples were then centrifuged at 10,000 × g 
for 15 min at 4 °C. The protein in the supernatant 
was quantified using a BCA protein assay kit. 
Malondialdehyde (MDA), glutathione (GSH) and 
superoxide dismutase (SOD) assay kits were 
used for measurement according to the 




Results from in vitro studies were carried out at 
least three times independently and were 
expressed as the mean ± standard error of the 
mean (SEM). Results from in vivo studies are 
shown as mean ± standard deviation. The data 
were analyzed using GraphPad Prism 5.0 
(GraphPad, San Diego, CA, USA). One-way 
analysis of variance (ANOVA) and the Student’s 
t-test were used to evaluate the statistical 





AN-1 protected SH-SY5Y cells against OGD-
induced cell death 
 
The cytotoxicity of AN-1 was first tested. The 
MTT results (Figure 1A) indicated that under 10 
μM, neither Apo nor AN-1 showed significant 
cytotoxicity in SH-SY5Y cells cultured under 
normal condition. However, both showed distinct 
cytotoxicity at 100 μM, and Apo was more toxic 
than AN-1. The test concentration of Apo and 
AN-1 was then controlled within 10 μM. As 
shown in Figure 1B, OGD insult resulted in death 
of SH-SY5Y cells. Compared with the control 
group, the cell viability of OGD group dropped 
from 95.0 to 25.3 % after 1 to 16 h of OGD insult, 
respectively. 56.0 % of cell survived when 
treated with OGD for 8 h, thus, the OGD insult 
duration was set 8 h. Figure 1C shows a low 
viability in OGD group, and demonstrates that 
Apo (10 μM) and Eda (1 μM) increased cell 
viability to 68.3 and 72.0 %, respectively. 
Meanwhile, AN-1 increased cell viability from 
58.0 % to 79.0 % in a concentration-dependent 
manner. 
 
AN-1 reversed OGD-induced intracellular 
ROS increase 
 
As shown in Figure 2, compared with the control, 
OGD treatment (1 h) significantly induced ROS 
production in SH-SY5Y cells. Apo and Eda 
substantially decreased the level of ROS, while 
AN-1 reversed the production of ROS in a 
concentration-dependent way. The ROS 
production in the AN-1 group was markedly lower 




Figure 1: Cell viability of SH-SY5Y cells measured 
using the MTT staining method (n = 3). A: Cytotoxicity 
of Apo and AN-1 in SH-SY5Y cells. B: Effect of OGD 
insult for different durations. C: Effect of the tested 
agents on OGD-treated (8 h) SH-SY5Y cells. ### p < 
0.001, ## p < 0.01, vs. control group; *** p < 0.001, ** p 
< 0.01, vs. OGD group.  
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AN-1 ameliorated neurological deficit in I/R 
rats  
 
The Longa method was adopted to assess the 
degree of neurological deficit of I/R rats after 
dosing of the tested agents. As shown in Figure 
3, rats in the I/R model group scored 2.5 after 
ischemia reperfusion. Apo and Eda decreased 
the scores to 1.3 and 1.1, respectively. AN-1 at 
1.5 mg/kg played no role in ameliorating the 
neurological deficit, but reduced the neurological 





Figure 2: Influence of Eda, Apo and AN-1 on the intracellular ROS production of SH-SY5Y cells with OGD 
treatment (1 h) measured by flow cytometer (n = 3). A: Representative pictures of DCF-derived fluorescence in 
SH-SY5Y cells exposed to OGD insult with treatment of different agents. B: Quantitative analysis of the mean 
fluorescence intensity of DCF in different groups. Results were expressed as percentage of the control group. ### 
p < 0.001, vs. control group. *** p < 0.001, ** p < 0.01, vs. OGD group 
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Figure 3: Effect of Eda, Apo and AN-1 on the 
neurological deficit scores of I/R rats (n = 10). *** p < 
0.001, ** p < 0.01, * p < 0.05, vs. I/R group 
 
     
Figure 4: Cerebral infract area of I/R rats with 
treatment of Eda, Apo and AN-1 (n = 10). A: 
Representative photos of brain sections stained by 
TTC. Red regions represent normal cells, whereas 
white regions are necrotic cells. *** p < 0.001, vs. I/R 
group 
 
AN-1 reduced the MCAO-induced cerebral 
infarct area in rats 
 
No infarct was observed in the brains of rats in 
 the control group. However, large infract area 
was observed in the brains of I/R model rats. 
When treated with Apo (2 mg/kg), Eda (6 mg/kg) 
and AN-1 (3 and 6 mg/kg), the MCAO-induced 
cerebral infarct area in I/R rats was significantly 
reduced (p < 0.001). As shown in Figure 4A and 
4B, the cerebral infarct area (%) in I/R model rats 
was 46.4 %. Both Apo and Eda reduced the 
infarct area (%) to 24.8 %. AN-1 reduced the 
infarct area to 27.0 and 19.1 % at 3 and 6 mg/kg, 
respectively. 
 
AN-1 reduced oxidative stress in I/R rats 
 
Compared with the shame-operated control 
group (Figure 5), the production of MDA 
increased by 151.6 %, and the level of SOD and 
GSH decreased by 59.9 and 63.7 %, 
respectively, in the brains of I/R model rats. 
Compared with the I/R model group, Eda and 
Apo significantly reversed the MDA increase (to 
61.0 and 68.3 % of the I/R model group), SOD 
decrease (to 180.1 and 173.0 % of the I/R model 
group), and GSH decrease (to 194.9 and 155.1 
% of the I/R model group). AN-1 reduced the 
production of MDA to 87.6, 68.0 and 45.6 % of 
the I/R model group at dose of 1.5, 3.0 and 6.0 
mg/kg, respectively. Although AN-1 showed no 
distinct action to increase the level of SOD and 
GSH at 1.5 mg/kg, it enhanced the SOD (to 
148.4 and 228.4 % of the I/R model group) and 
GSH (to 157.7 and 232.1 % of the I/R model 




Ischemic stroke results from blockage of blood 
supply to the brain. It brings irreversible injury of 
brain tissue if the cerebral blood vessel cannot 
be recanalized timely. Clinically, quick 
thrombolysis to restore blood flow as early as 
possible is recommended for the treatment of 
ischemic stroke [3]. The only proven thrombolytic 
therapy for acute ischemic stroke was achieved 
by intravenous use of t-PA. However, less than 
10 % of patients with ischemic stroke may benefit 
from t-PA treatment because of the strict 
eligibility criteria for its use, including a relatively 
short therapeutic time window less than 4.5 h 
[21]. Follow-up care after blood flow restoration is 
also of great concern because I/R leads to 
serious brain injury [22,23]. Neuroprotective 
agents are thus urgently needed along with 
thrombolytic treatment to protect neurons from  
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Figure 5: Effects of Eda, Apo and AN-1 on the levels 
of SOD (A), GSH (B) and MDA (C) in the ischemic 
brain of I/R rats (n = 10). ### p < 0.001, vs. sham 
group.*** p < 0.001, ** p < 0.01, * p < 0.05, vs. I/R 
group 
 
damage. Edaravone is an important agent, which 
was luached in Japan as a therapeutic for 
ischemic stroke through neuroprotection by free 
radical scavenging in 2001. However, some 
researchers have reported serious adverse 
reactions resulting from the use of Eda, including 
renal and hepatic disorders, this may partially 
account for its limited use [24,25]. While 
substantial numbers of experimental drugs have 
been investigated, so far, acute pharmacological 
intervention with neuroprotective agents has not 
been successful [2,4].  
 
Oxidative stress is one of the prevalent factors in 
the development cascade of I/R injury from 
stroke [3,4,11,22,23]. As a NOX inhibitor, 
apocynin is a widely investigated anti-oxidative 
and anti-inflammatory agent [26]. Apocynin 
alleviated oxidative stress after I/R and 
demonstrated neuroprotective action in I/R 
MCAO mice by NOX inhibition [27]. Nitrone 
compounds, representing a group of free radical 
traps [11,12], demonstrated effective 
neuroprotection in animal stroke models [28,29]. 
In this work, AN-1 was synthesized by 
conjugating apocynin with nitrone to elicit potent 
neuroprotective action through oxidative stress 
amelioration. 
 
In SH-SY5Y cells, AN-1 showed lower 
cytotoxicity than Apo at a high concentration, cell 
viability was almost 1.5-fold as much as that of 
Apo. At the same concentration, AN-1 was more 
powerful than Apo when it came to protect cells 
from OGD insult (p < 0.05). Moreover, the 
intracellular ROS production in the AN-1 group 
was 41.2 and 74.0 % of that in the Apo and Eda 
groups, indicating better antioxidant activity. 
 
In MCAO model rats, AN-1 dose-dependently 
ameliorated neurological deficit induced by 
ischemia-reperfusion, although it exhibited no 
significant difference from the activity of Apo and 
Eda. The efficacy of AN-1 is similar to that of 
apocynin, while it is significantly greater than that 
of Eda in lessening cerebral infarct rate and 
palliating oxidative stress in the ischemic 
hemisphere (p < 0.05). The results in vitro and in 
vivo demonstrated that AN-1 has distinct anti-
oxidative potency, which may be one of the chief 
mechanisms accounting for its neuroprotective 
action. 
 
However, different researchers have reported 
widely different effective doses of Apo. Tang et al 
found that Apo improved neurological function (p 
< 0.01), and reduced the infarct volume (p < 
0.05) and incidence of cerebral hemorrhage (p < 
0.05) in mice when administered intravenously at 
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3.75 and 5 mg/kg, where it actually increased 
brain hemorrhage [9]. Interestingly, another 
group reported that Apo at 50 mg/kg attenuated 
cerebral infarction after transient focal ischemia 
in male SD rats [30]. In this study, Apo showed 
significant protective effect against MCAO-
induced impairment at 2 mg/kg in male SD rats, 
while it easily triggered brain hemorrhage at 50 
mg/kg in a trial test. Our results were inconsistent 




AN-1 enhances the cell survival rate and 
suppresses the over-production of ROS in OGD-
treated SH-SY5Y cells. It protects ischemia-
reperfusion rats from neurological deficit by 
alleviating cerebral infarction and oxidative 
stress, suggesting that AN-1 may be a potential 
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